How do I install the Glycoengineering skill?

Run npx skillmds@latest add mkurman/glycoengineering in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Glycoengineering safe to use?

This skill has not completed SkillMD's automated safety review yet. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Glycoengineering?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Glycoengineering free to use?

Yes. Installing skills from SkillMD is free. This skill is licensed under Unknown.

Who published Glycoengineering?

mkurman (@mkurman) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Glycoengineering by mkurman — Agent Skill

Name: Glycoengineering
Author: mkurman

Glycoengineering

Analyze and engineer protein glycosylation. Scan sequences for N-glycosylation sequons (N-X-S/T), predict O-glycosylation hotspots, and access curated glycoengineering tools (NetOGlyc, GlycoShield, GlycoWorkbench). For glycoprotein engineering, therapeutic antibody optimization, and vaccine design.

mkurman e93dc5c 2 files · 8.4 KB Updated Sep 17, 2026

File contents

|----------|-------| | Enhance ADCC | Defucosylation at Fc Asn297 | Afucosylated IgG1 has ~50× better FcγRIIIa binding | | Reduce immunogenicity | Remove non-human glycans | Eliminate α-Gal, NGNA epitopes | | Improve PK half-life | Sialylation | Sialylated glycans extend half-life | | Reduce inflammation | Hypersialylation | IVIG anti-inflammatory mechanism | | Create glycan shield | Add N-glycosites to surface | Masks vulnerable epitopes (vaccine design) |

Common Mutations Used

Mutation	Effect
N297A/Q (IgG1)	Removes Fc glycosylation (aglycosyl)
N297D (IgG1)	Removes Fc glycosylation
S298A/E333A/K334A	Increases FcγRIIIa binding
F243L (IgG1)	Increases defucosylation
T299A	Removes Fc glycosylation

Glycan Notation

IUPAC Condensed Notation (Monosaccharide abbreviations)

Symbol	Full Name	Type
Glc	Glucose	Hexose
GlcNAc	N-Acetylglucosamine	HexNAc
Man	Mannose	Hexose
Gal	Galactose	Hexose
Fuc	Fucose	Deoxyhexose
Neu5Ac	N-Acetylneuraminic acid (Sialic acid)	Sialic acid
GalNAc	N-Acetylgalactosamine	HexNAc

Complex N-Glycan Structure

Typical complex biantennary N-glycan:
Neu5Ac-Gal-GlcNAc-Man\
                       Man-GlcNAc-GlcNAc-[Asn]
Neu5Ac-Gal-GlcNAc-Man/
(±Core Fuc at innermost GlcNAc)

Best Practices

Start with NetNGlyc/NetOGlyc for computational prediction before experimental validation
Verify with mass spectrometry: Glycoproteomics (Byonic, Mascot) for site-specific glycan profiling
Consider site context: Not all predicted sequons are actually glycosylated (accessibility, cell type, protein conformation)
For antibodies: Fc N297 glycan is critical — always characterize this site first
Use GlyConnect to check if your protein of interest has experimentally verified glycosylation data

Additional Resources

GlyTouCan (glycan structure repository): https://glytoucan.org/
GlyConnect: https://glyconnect.expasy.org/
CFG Functional Glycomics: http://www.functionalglycomics.org/
DTU Health Tech servers (NetNGlyc, NetOGlyc): https://services.healthtech.dtu.dk/
GlycoWorkbench: https://glycoworkbench.software.informer.com/
Review: Apweiler R et al. (1999) Biochim Biophys Acta. PMID: 10564035
Therapeutic glycoengineering review: Jefferis R (2009) Nature Reviews Drug Discovery. PMID: 19448661

---name: glycoengineeringdescription: Analyze and engineer protein glycosylation. Scan sequences for N-glycosylation sequons (N-X-S/T), predict O-glycosylation hotspots, and access curated glycoengineering tools (NetOGlyc, GlycoShield, GlycoWorkbench). For glycoprotein engineering, therapeutic antibody optimization, and vaccine design.license: Unknown---|----------|-------|| Enhance ADCC | Defucosylation at Fc Asn297 | Afucosylated IgG1 has ~50× better FcγRIIIa binding || Reduce immunogenicity | Remove non-human glycans | Eliminate α-Gal, NGNA epitopes || Improve PK half-life | Sialylation | Sialylated glycans extend half-life || Reduce inflammation | Hypersialylation | IVIG anti-inflammatory mechanism || Create glycan shield | Add N-glycosites to surface | Masks vulnerable epitopes (vaccine design) |### Common Mutations Used| Mutation | Effect ||----------|--------|| N297A/Q (IgG1) | Removes Fc glycosylation (aglycosyl) || N297D (IgG1) | Removes Fc glycosylation || S298A/E333A/K334A | Increases FcγRIIIa binding || F243L (IgG1) | Increases defucosylation || T299A | Removes Fc glycosylation |## Glycan Notation### IUPAC Condensed Notation (Monosaccharide abbreviations)| Symbol | Full Name | Type ||--------|-----------|------|| Glc | Glucose | Hexose || GlcNAc | N-Acetylglucosamine | HexNAc || Man | Mannose | Hexose || Gal | Galactose | Hexose || Fuc | Fucose | Deoxyhexose || Neu5Ac | N-Acetylneuraminic acid (Sialic acid) | Sialic acid || GalNAc | N-Acetylgalactosamine | HexNAc |### Complex N-Glycan Structure```Typical complex biantennary N-glycan:Neu5Ac-Gal-GlcNAc-Man\ Man-GlcNAc-GlcNAc-[Asn]Neu5Ac-Gal-GlcNAc-Man/(±Core Fuc at innermost GlcNAc)```## Best Practices- **Start with NetNGlyc/NetOGlyc** for computational prediction before experimental validation- **Verify with mass spectrometry**: Glycoproteomics (Byonic, Mascot) for site-specific glycan profiling- **Consider site context**: Not all predicted sequons are actually glycosylated (accessibility, cell type, protein conformation)- **For antibodies**: Fc N297 glycan is critical — always characterize this site first- **Use GlyConnect** to check if your protein of interest has experimentally verified glycosylation data## Additional Resources- **GlyTouCan** (glycan structure repository): https://glytoucan.org/- **GlyConnect**: https://glyconnect.expasy.org/- **CFG Functional Glycomics**: http://www.functionalglycomics.org/- **DTU Health Tech servers** (NetNGlyc, NetOGlyc): https://services.healthtech.dtu.dk/- **GlycoWorkbench**: https://glycoworkbench.software.informer.com/- **Review**: Apweiler R et al. (1999) Biochim Biophys Acta. PMID: 10564035- **Therapeutic glycoengineering review**: Jefferis R (2009) Nature Reviews Drug Discovery. PMID: 19448661

Frequently asked questions